Literature DB >> 33796185

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma: clinicopathological study and treatment outcome in 50 patients.

Yosr Zenzri1, Lamia Charfi1, Ghada Sahraoui1, Yosra Yahyaoui2, Karima Mrad1, Nadia Boujelbene1, Raoudha Doghri1.   

Abstract

The stomach is the most frequent site of extranodal lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade, B-cell neoplasm strongly associated with Helicobacter pylori (HP) infection. The presenting complaints of gastric MALT lymphoma are usually nonspecific. HP eradication is regarded as the first-line therapy in early stage disease. Management of patients who failed to achieve remission following HP eradication include chemotherapy, radiotherapy and in selected cases, surgery. The aim of the present study was to examine the clinical characteristics and treatment outcome of patients with gastric MALT lymphoma. Copyright: Yosr Zenzri et al.

Entities:  

Keywords:  Mucosa-associated lymphoid tissue; lymphoma; prognosis; treatment

Mesh：

Year:  2020        PMID： 33796185      PMCID： PMC7992398          DOI： 10.11604/pamj.2020.37.372.27094

Source DB:  PubMed          Journal:  Pan Afr Med J


  8 in total

1.  Gastric malt lymphoma: Analysis of a series of consecutive patients over 20 years.

Authors:  Joana Moleiro; Sara Ferreira; Pedro Lage; A Dias Pereira
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

Review 2.  Clinical aspects and therapy of gastrointestinal MALT lymphoma.

Authors:  Catherine Thieblemont; Emanuele Zucca
Journal:  Best Pract Res Clin Haematol       Date:  2017-01-30       Impact factor: 3.020

3.  Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group.

Authors:  W Fischbach; B Dragosics; M E Kolve-Goebeler; C Ohmann; A Greiner; Q Yang; S Böhm; P Verreet; O Horstmann; M Busch; E Dühmke; H K Müller-Hermelink; K Wilms; S Allinger; P Bauer; S Bauer; A Bender; G Brandstätter; A Chott; C Dittrich; K Erhart; D Eysselt; H Ellersdorfer; A Ferlitsch; M A Fridrik; A Gartner; M Hausmaninger; W Hinterberger; K Hügel; P Ilsinger; K Jonaus; G Judmaier; J Karner; E Kerstan; P Knoflach; K Lenz; A Kandutsch; M Lobmeyer; H Michlmeier; H Mach; C Marosi; W Ohlinger; H Oprean; H Pointer; J Pont; H Salabon; H J Samec; A Ulsperger; A Wimmer; F Wewalka
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

4.  Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice.

Authors:  Christiane Copie-Bergman; Andrew C Wotherspoon; Carlo Capella; Teresio Motta; Ennio Pedrinis; Stefano A Pileri; Francesco Bertoni; Annarita Conconi; Emanuele Zucca; Maurilio Ponzoni; Andrés J M Ferreri
Journal:  Br J Haematol       Date:  2012-10-09       Impact factor: 6.998

5.  Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter?

Authors:  Barbara Kiesewetter; Julius Lukas; Werner Dolak; Ingrid Simonitsch-Klupp; Marius E Mayerhoefer; Markus Raderer
Journal:  Oncology       Date:  2016-08-23       Impact factor: 2.935

Review 6.  Primary low-grade and high-grade gastric MALT-lymphoma presentation.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Andriani; Francesca Cristofari; Vincenzo Cardinale; Gian Paolo Spinelli; Silverio Tomao; Sergio Morini
Journal:  J Clin Gastroenterol       Date:  2010 May-Jun       Impact factor: 3.062

Review 7.  Gastric MALT lymphoma: old and new insights.

Authors:  Angelo Zullo; Cesare Hassan; Lorenzo Ridola; Alessandro Repici; Raffaele Manta; Alessandro Andriani
Journal:  Ann Gastroenterol       Date:  2014

8.  Clinical characteristics and prognostic factors of primary gastric lymphoma: A retrospective study with 165 cases.

Authors:  Yi-Gao Wang; Lin-Yong Zhao; Chuan-Qi Liu; Si-Cheng Pan; Xiao-Long Chen; Kai Liu; Wei-Han Zhang; Kun Yang; Xin-Zu Chen; Bo Zhang; Zhi-Xin Chen; Jia-Ping Chen; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.